ReviewCardiovascular & hematological disorders drug targets2026
A Clinical Review on HMG-CoA Reductase Inhibitors (Statins)-induced Hyperglycemia and New-onset Diabetes Mellitus (NODM).
Review in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDue to their potent lipid-lowering capabilities, 3-hydroxy-3- methylglutyryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins, are widely utilized for the primary and secondary prevention of cardiovascular disease. However, there is growing evidence that statin use may be associated with an increased risk of hyperglycemia and new-onset diabetes mellitus (NODM). This narrative review aims to summarize current understanding of statin-induced NODM by examining clinical data, potential mechanisms, risk factors, and the clinical consequences of statin-induced diabetes and hyperglycemia.
methodsA comprehensive literature search was conducted using online databases such as Medline/ PubMed/PMC, Scopus, Web of Science, and Google Scholar, as well as reference lists, to locate clinical evidence on statin-induced NODM. Meta-analyses, observational studies, and randomized controlled trials (RCTs) were assessed.
resultsSeveral randomized controlled clinical trials, meta-analyses, and observational studies examined the incidence of NODM associated with statin therapy. Seven clinical studies and 25 meta-analyses have been included in this current review. DISCUSSION: Long-term statin users were found to have a higher risk of NODM, according to the JUPITER, WOSCOPS, PROSPER, PROVE-IT TIMI 22, and ASCOT-LLA studies. Furthermore, several meta-analyses found a connection between statin use and a higher risk of NODM.
conclusionBased on the clinical studies and meta-analyses included in this review, the risk of occurrence of NODM among long-term statin users was found to be higher. The review examined several potential mechanisms, such as altered glucose metabolism, decreased insulin sensitivity, and impaired insulin secretion. Risk factors such as age, obesity, high-intensity statin regimens, and pre-existing impaired glucose tolerance are covered in detail. To maximize patient results, a customized strategy to statin prescription and treatment is essential, even if the cardiovascular benefits of statins typically outweigh the risk of NODM, particularly in high-risk individuals.
Indexed as
Identifiers
41941295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.